AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and Processes
IncretinsGastric Inhibitory PolypeptideGlucagon-Like Peptide 1Dipeptidyl-Peptidase IV InhibitorsDipeptidyl Peptidase 4Glucagon-Like PeptidesReceptors, GlucagonGastric BypassDiabetes Mellitus, Type 2GlucagonObesity, MorbidBariatric SurgeryInsulinInsulin-Secreting CellsBlood GlucoseHypoglycemic AgentsPostprandial PeriodGlucoseGlucose Tolerance Test
MimeticsHormonesSecretionHypoglycemic agentsAgonistsInsulinotropicHormoneHyperglycemiaBlood glucoseLiraglutidePancreatic cancer associatedGlucagonReceptorPeptidesTherapies for type 2 diabet2022TherapeuticTherapyT2DMDiabetes mellitusPancreasDrugsEfficacyMedicationsTypeHumansPhysiologicalEffectRelevancePotentialLevels
Mimetics5
  • In conclusion, longer-term administration of apelin-13 analogues, induced similar and in some respects more effective metabolic improvements than incretin mimetics in db/db mice, providing a viable alternative approach for counteracting metabolic dysfunction for mild and more degenerative forms of the disease. (ulster.ac.uk)
  • Further studies examined the impact of JMV-449 and incretin mimetics on glucose homeostasis and appetite control in mice. (ulster.ac.uk)
  • In re Incretin Mimetics Products Liability Litigation , MDL 2452 (S.D. Cal. (dlapiper.com)
  • Semaglutide is in a class of medications called incretin mimetics. (medlineplus.gov)
  • GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics. (iric.ca)
Hormones14
  • Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate insulin secretion together with hyperglycaemia. (nih.gov)
  • GIP (glucose-dependent insulinotropic polypeptide) und GLP-1 (glucagon-like peptide-1) are the known incretin hormones from the upper (GIP, K cells) and lower (GLP-1, L cells) gut. (nih.gov)
  • Incretins are a group of metabolic hormones that stimulate a decrease in blood glucose levels. (wikipedia.org)
  • Incretin hormones inherently work by being released in the gastrointestinal (GI) tract in response to glucose consumption, thereby increasing insulin secretion by the pancreas and decreasing glucagon production, ultimately leading to lower sugars. (uspharmacist.com)
  • The incretins are gastrointestinal polypeptide hormones that act to modulate insulin secretion from pancreatic beta cells. (nih.gov)
  • Review GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. (nih.gov)
  • Blood collection tubes containing a DPP‐4 inhibitor must be used in measuring levels of active incretin hormones. (or.jp)
  • Plasma samples are not necessarily extracted in case of measuring levels of total (active plus DPP‐4‐inactivated) incretins hormones. (or.jp)
  • We measured secretion of these hormones and cardiac repolarization in response to glucose ingestion in LQT2 patients with functional mutations in hERG and matched healthy participants, testing the hypothesis that LQT2 patients have increased incretin and β cell- and decreased α cell function and thus lower glucose levels. (ku.dk)
  • The incretin hormones GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are released from the intestine after food ingestion to stimulate insulin secretion in a glucose-dependent manner. (lu.se)
  • The long-lasting derivatives of the insulinotropic incretin hormones-glucagonlike peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)-have repeatedly been shown to cross the blood-brain barrier and counteract an array of deleterious effects across a range of experimental models of neuronal degeneration. (nih.gov)
  • Agonists of gut-derived glucagon-like peptide-1 (GLP-1), gastrointestinal hormones able to increase insulin secretion in response to hyperglycaemia (incretins), have been recently introduced in T2DM therapy, quickly entering the international guidelines. (unipa.it)
  • It can increase the endogenous incretin hormones by inhibition of their degradation. (rug.nl)
  • Enteroendocrine hormones, two incretins in particular - glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) - play a vital role in metabolism. (nih.gov)
Secretion5
  • Incretins are released after eating and augment the secretion of insulin released from pancreatic beta cells of the islets of Langerhans by a blood-glucose-dependent mechanism. (wikipedia.org)
  • Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are the two incretins that have been identified as primarily responsible for postprandial insulin secretion, with GIP being the predominant incretin to release insulin in response to glucose intake. (uspharmacist.com)
  • 3 The GLP-1 incretin promotes satiety, slows gastric emptying, decreases glucagon secretion, and decreases food intake, resulting in weight loss. (uspharmacist.com)
  • Glucagon concentrations can be elevated in diabetes due to dysregulation of glucagon secretion, while the pancreatic beta-cell can be resistant to the insulinotropic effects of the incretins, both contributing to hyperglycemia. (nih.gov)
  • The goal of the study extension is to see whether the incretin hormone GIP increases insulin secretion in individuals with CF and normal glucose tolerance compared to individuals without CF and normal glucose tolerance. (chop.edu)
Hypoglycemic agents1
  • These incretin-based hypoglycemic agents are relatively new and they have not been implicated as common causes of drug induced liver injury. (nih.gov)
Agonists4
  • Thus, it has become a parent compound of incretin-based glucose-lowering medications (GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4 or DPP-4). (nih.gov)
  • The concerns about pancreatitis and pancreatic cancer relate to some relatively new type 2 diabetes drugs, the glucagonlike peptide-1 (GLP-1) agonists and dipeptidyl peptidase (DPP-4) inhibitors, collectively known as GLP-1-based drugs, or "incretins. (medscape.com)
  • The observation that the insulinotropic actions of GLP-1 are reduced in type 2 diabetes mellitus (T2DM) led to the development of incretin-based therapies - GLP-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors - for the treatment of hyperglycaemia in these patients. (nih.gov)
  • Although medications to treat obesity have a history of safety concerns and only modest efficacy, new and emerging pharmacotherapeutic options-including single, dual, and poly-incretin agonists-are changing the treatment landscape, with significantly greater weight loss efficacy than previous treatments. (nih.gov)
Insulinotropic2
  • The two main candidate peptides that fulfill criteria for an incretin are the intestinal peptides glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP, also known as: glucose-dependent insulinotropic polypeptide). (wikipedia.org)
  • However, Kv11.1 is also present in pancreatic α and β cells and intestinal L and K cells, secreting glucagon, insulin, and the incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), respectively. (ku.dk)
Hormone3
  • In 1932, Belgian physiologist Jean La Barre used the word "incretin" for a gut hormone, which stimulates the endocrine pancreas including insulin release. (wikipedia.org)
  • Role of the incretin hormone GIP in the development of diabetic vascular complications - good or bad? (lu.se)
  • The gut-derived incretin hormone glucagon-like peptide 1 (GLP-1) is secreted upon meal ingestion and controls glucose metabolism by modulating pancreatic islet cell function, food intake and gastrointestinal motility, amongst other effects. (nih.gov)
Hyperglycemia1
  • Incretin dysfunction and hyperglycemia in cystic fibrosis: Role of acyl-ghrelin. (nih.gov)
Blood glucose1
Liraglutide3
  • Aim To review the effi cacy and safety data on incretin-based therapies currently available (exenatide, liraglutide, sitagliptin, vildagliptin) for the treatment of type 2 diabetes mellitus in Asian population. (ui.ac.id)
  • It was shown that incretin-based therapies improved HbA1c at higher extent (up to -1.42% in exenatide 10 mcg bid, -1.85% for liraglutide 0.9 mg qd, -1.4% for sitagliptin 100 mg and -1.4% for vildagliptin 50 mg bid) compared to the effects observed in studies with Caucasian population, with comparable safety profile. (ui.ac.id)
  • i.p.) or saline vehicle, apelin amide, apelin FA, or the established incretin therapies, exendin-4(1-39) or liraglutide, all at 25 nmol/kg body weight for 21 days. (ulster.ac.uk)
Pancreatic cancer associated2
  • The meeting experts concluded that currently there is little evidence of an increased risk of pancreatic cancer associated with incretin use. (medscape.com)
  • the overriding conclusion was that currently there seems to be little evidence for an increased risk for pancreatic cancer associated with use of incretin therapies. (medscape.com)
Glucagon1
  • Some incretins (GLP-1) also inhibit glucagon release from the alpha cells of the islets of Langerhans. (wikipedia.org)
Receptor1
  • These observations emphasise the, yet untapped, therapeutic potential of combined neurotensin and incretin receptor signalling for diabetes. (ulster.ac.uk)
Peptides1
Therapies for type 2 diabet3
  • These findings illustrate the need for continued education for healthcare professionals on the use of incretin therapies for type 2 diabetes. (clinicaloptions.com)
  • Incretin-based therapies are now the most promising therapies for type 2 diabetes. (formularywatch.com)
  • Methods We conducted Medline search of all relevant randomized clinical trials of incretin-based therapies for type 2 diabetes mellitus in Asian populations. (ui.ac.id)
20221
  • This poster, presented at ENDO 2022, summarizes key findings from an interim analysis of an online educational program, " Incretins Update: A Holistic Approach to Patients With Type 2 Diabetes and Cardiometabolic Comorbidities ," developed by Clinical Care Options in partnership with the Endocrine Society. (clinicaloptions.com)
Therapeutic2
  • application of incretin-based therapy: Therapeutic potential, patient selection and clinical use. (ui.ac.id)
  • Collectively, our findings endorse the beneficial effects of the incretin-based therapeutic approaches for the neurotrophic support of the AD brain and for the first time associate the incretin-induced neuroprotection with the proteostasis machinery in vivo . (nih.gov)
Therapy6
  • In the meantime, doctors are being urged to discuss the potential side effects of incretin-based therapy and the symptoms of pancreatitis with patients, especially those with other risk factors for the condition, and to balance the risks and benefits. (medscape.com)
  • Clinicians should discuss the potential side effects of incretin-based therapy and the symptoms of pancreatitis with patients, especially those with other risk factors for the condition, and balance the risks and benefits, it states. (medscape.com)
  • The incretin pathway provides several potential targets for therapy of type 2 diabetes, the main ones being DPP-4 inhibitors and GLP-1 analogues. (nih.gov)
  • Results We found 14 randomized controlled trials of incretin based-therapy which included 3567 type 2 diabetes mellitus in Asian population (Japanese, Chinese, Korean, Indian). (ui.ac.id)
  • EVOO's Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy? (unipa.it)
  • In this review, we explore observations regarding the pathophysiological basis of the existence of an enhanced effect between the action of EVOO and incretins and, consequently, try to understand whether there is a rationale for their use in combination for T2DM therapy. (unipa.it)
T2DM1
Diabetes mellitus3
  • Medications based on incretins are used in the treatment of diabetes mellitus type 2. (wikipedia.org)
  • He also proposed that such incretins could be used as a treatment for diabetes mellitus. (wikipedia.org)
  • Review Incretins: their physiology and application in the treatment of diabetes mellitus. (nih.gov)
Pancreas3
  • This is the consequence of a substantially reduced effectiveness of GIP on the diabetic endocrine pancreas, and of the negligible physiological role of GLP-1 in mediating the incretin effect even in healthy subjects. (nih.gov)
  • 3,4 Referred to as the incretin effect , they exert their effects by binding to their respective receptors of the pancreas' beta cells to ultimately release insulin. (uspharmacist.com)
  • D) Reagents and assays for the accurate expression and quantitation of functional incretin receptors in the endocrine/exocrine cells of the pancreas and relevant extrapancreatic tissues. (nih.gov)
Drugs6
  • These two groups of incretin-based drugs are quite different in chemical structure, pharmacology and safety profile and are discussed separately. (nih.gov)
  • OBJECTIVE: To determine whether the use of incretin based drugs compared with sulfonylureas is associated with an increased risk of incident pancreatic cancer in people with type 2 diabetes. (mcmaster.ca)
  • Hazard ratios and 95% confidence intervals for incident pancreatic cancer were estimated, comparing use of incretin based drugs with use of sulfonylureas, with drug use lagged by one year for latency purposes. (mcmaster.ca)
  • Compared with sulfonylureas, incretin based drugs were not associated with an increased risk of pancreatic cancer (pooled adjusted hazard ratio 1.02, 95% confidence interval 0.84 to 1.23). (mcmaster.ca)
  • CONCLUSIONS: In this large, population based study the use of incretin based drugs was not associated with an increased risk of pancreatic cancer compared with sulfonylureas. (mcmaster.ca)
  • Although this potential adverse drug reaction will need to be monitored long term owing to the latency of the cancer, these findings provide some reassurance on the safety of incretin based drugs. (mcmaster.ca)
Efficacy1
  • Conclusion The efficacy of incretin-based therapies in Asian patients improved glycemic parameters in a higher magnitude on some glycemic parameters compared with those in Caucasian population. (ui.ac.id)
Medications1
  • Incretin-based medications for type 2 diabetes: an overview of reviews. (mun.ca)
Type5
  • In subjects with type 2 diabetes, this incretin effect is diminished or no longer present. (nih.gov)
  • SAN FRANCISCO - The Endocrine Society is the latest organization to issue a statement indicating that more research is needed before any conclusion can be reached about a possible link between incretin-based type 2 diabetes therapies and pancreatic cancer. (medscape.com)
  • Dr. Mike Eades looks at the role Incretins play in the pathogenesis of Type 2 diabetes and obesity. (lowcarbconferences.com)
  • incretin effect in type 2 (non-insulin-dependent) diabetes. (ui.ac.id)
  • Carmot Therapeutics announced today the initiation of a clinical trial for the treatment of type 2 diabetes with CT-868, a dual modulator of the GLP-1 and GIP incretin receptors. (biospace.com)
Humans1
  • With the launch of incretin agents, there will be an increased need for incretin (GIP and GLP‐1) concentration measurements in humans. (or.jp)
Physiological1
  • These observations suggest that GLP-1 7-36 is a physiological incretin and that it is more powerful than GIP. (nih.gov)
Effect4
  • Together, they are responsible for the incretin effect: a two- to three-fold higher insulin secretory response to oral as compared to intravenous glucose administration. (nih.gov)
  • The incretin effect describes the phenomenon whereby oral glucose intake elicits a higher insulin response compared to intravenously introduced glucose that produces the same levels of serum glucose levels. (wikipedia.org)
  • Although a slightly increased risk of pancreatitis associated with incretins is well recognized and noted in the labeling of these products, there is unease about the potential of a class carcinogenic effect. (medscape.com)
  • The Incretin Effect in. (checkorphan.org)
Relevance1
  • 26: 1770 - 80.Seino Y. Relevance of incretins in the treatment of Asian patients 10. (ui.ac.id)
Potential1
Levels1
  • It is essential that plasma samples are extracted prior to measurement of active incretin levels. (or.jp)